Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Environ Monit Assess ; 189(10): 485, 2017 Sep 04.
Artículo en Inglés | MEDLINE | ID: mdl-28871518

RESUMEN

The assessment of nitrous oxide (N2O) fluxes from agricultural soil surfaces still poses a major challenge to the scientific community. The evaluations of integrated soil fluxes of N2O are difficult owing to their lower emissions when compared with CO2. These emissions are also sporadic as environmental conditions act as a limiting factor. A station prototype was developed to integrate annual N2O and CO2 emissions using an automatic chamber technique and infrared spectrometers within the LIFE project (IPNOA: LIFE11 ENV/IT/00032). It was installed from June 2014 to October 2015 in an experimental maize field in Tuscany. The detection limits for the fluxes were evaluated up to 1.6 ng N-N2O m2 s-1 and 0.3 µg C-CO2 m2 s-1. A cross-comparison carried out in September 2015 with the "mobile IPNOA prototype"; a high-sensibility transportable instrument already validated provided evidence of very similar values and highlighted flux assessment limitations according to the gas analyzers used. The permanent monitoring device showed that temporal distribution of N2O fluxes can be very large and discontinuous over short periods of less than 10 days and that N2O fluxes were below the detection limit of the instrumentation during approximately 70% of the measurement time. The N2O emission factors were estimated to 1.9% in 2014 and 1.7% in 2015, within the range of IPCC assessments.


Asunto(s)
Contaminantes Atmosféricos/análisis , Monitoreo del Ambiente/métodos , Óxido Nitroso/análisis , Suelo/química , Agricultura/métodos , Dióxido de Carbono/análisis , Monitoreo del Ambiente/instrumentación , Italia , Límite de Detección , Estaciones del Año , Zea mays/crecimiento & desarrollo
3.
Int J Immunopathol Pharmacol ; 20(3): 473-85, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17880761

RESUMEN

In some early-treated HIV-positive patients, Structured Treatment Interruption (STI) is associated to spontaneous control of viral rebound. Thus, in this clinical setting, we analyzed the immunological parameters associated to viral control. Two groups of early treated patients who underwent STI were retrospectively defined, according to the ability to spontaneously control HIV replication (Controller and Non-controller). Plasma cytokine levels were analyzed by multiplex analysis. CD8 T cell differentiation was determined by polychromatic flow cytometry. Antigen-specific IFN-gamma production was analyzed by ELISpot and intracellular staining after stimulation with HIV-peptides. Long-term Elispot assays were performed in the presence or absence of IL-15. Plasma IL-15 was found decreased over a period of time in Non-Controller patients, whereas a restricted response to Gag (aa.167-202 and 265-279) and Nef (aa.86-100 and 111-138) immunodominant epitopes was more frequently observed in Controller patients. Interestingly, in two Non-Controller patients the CD8-mediated T cells response to immunodominant epitopes could be restored in vitro by IL-15, suggesting a major role of cytokine homeostasis on the generation of protective immunity. In early-treated HIV+ patients undergoing STI, HIV replication control was associated to CD8 T cell maturation and sustained IL-15 levels, leading to HIV-specific CD8 T cell responses against selected Gag and Nef epitopes.


Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Linfocitos T CD8-positivos/efectos de los fármacos , Epítopos/inmunología , Antígenos VIH/inmunología , Infecciones por VIH , Interleucina-15/inmunología , Adulto , Fármacos Anti-VIH/administración & dosificación , Terapia Antirretroviral Altamente Activa , Linfocitos T CD8-positivos/inmunología , Epítopos/farmacología , Antígenos VIH/farmacología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/inmunología , VIH-1/fisiología , Humanos , Memoria Inmunológica/efectos de los fármacos , Interferón gamma/inmunología , Interleucina-15/sangre , Interleucina-15/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Leucocitos Mononucleares/inmunología , Masculino , Persona de Mediana Edad , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/farmacología , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/farmacología , Replicación Viral/efectos de los fármacos , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen gag del Virus de la Inmunodeficiencia Humana/farmacología , Productos del Gen nef del Virus de la Inmunodeficiencia Humana/inmunología , Productos del Gen nef del Virus de la Inmunodeficiencia Humana/farmacología
4.
Cancer Gene Ther ; 14(9): 791-801, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17557110

RESUMEN

There is growing evidence that combinations of antiangiogenic proteins with other antineoplastic treatments such as chemo- or radiotherapy and suicide genes-mediated tumor cytotoxicity lead to synergistic effects. In the present work, we tested the activity of two non-replicative herpes simplex virus (HSV)-1-based vectors, encoding human endostatin::angiostatin or endostatin::kringle5 fusion proteins in combination with HSV-1 thymidine kinase (TK) molecule, on endothelial cells (ECs) and Lewis lung carcinoma (LLC) cells. We observed a significant reduction of the in vitro growth, migration and tube formation by primary ECs upon direct infection with the two recombinant vectors or cultivation with conditioned media obtained from the vector-infected LLC cells. Moreover, direct cytotoxic effect of HSV-1 TK on both LLC and ECs was demonstrated. We then tested the vectors in vivo in two experimental settings, that is, LLC tumor growth or establishment, in C57BL/6 mice. The treatment of pre-established subcutaneous tumors with the recombinant vectors with ganciclovir (GCV) induced a significant reduction of tumor growth rate, while the in vitro infection of LLC cells with the antiangiogenic vectors before their implantation in mice flanks, either in presence or absence of GCV, completely abolished the tumor establishment.


Asunto(s)
Carcinoma Pulmonar de Lewis/patología , Virus Defectuosos/genética , Herpesvirus Humano 1/genética , Neovascularización Patológica , Timidina Quinasa/genética , Replicación Viral , Animales , Células Cultivadas , Chlorocebus aethiops , Virus Defectuosos/enzimología , Virus Defectuosos/fisiología , Vectores Genéticos , Herpesvirus Humano 1/enzimología , Herpesvirus Humano 1/fisiología , Humanos , Ratones , Ratones Endogámicos C57BL , Células Vero
5.
Gene Ther ; 12(7): 559-69, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15616598

RESUMEN

Neurotrophic factors (NTFs) are known to govern the processes involved in central nervous system cell proliferation and differentiation. Thus, they represent very attractive candidates for use in the study and therapy of neurological disorders. We constructed recombinant herpesvirus-based-vectors capable of expressing fibroblast growth factor-2 (FGF-2) and ciliary neurotrophic factor (CNTF) alone or in combinations. In vitro, vectors expressing FGF-2 and CNTF together, but not those expressing either NTF alone, caused proliferation of O-2A progenitors. Furthermore, based on double-labeling experiments performed using markers for neurons (MAP-2), oligodendrocytes (CNPase) and astrocytes (GFAP), most of the new cells were identified as astrocytes, but many expressed neuronal or oligodendrocytic markers. In vivo, vectors have been injected in the rat hippocampus. At 1 month after inoculation, a highly significant increase in BrdU-positive cells was observed in the dentate gyrus of animals injected with the vector expressing FGF-2 and CNTF together, but not in those injected with vectors expressing the single NTFs. Furthermore, double-labeling experiments confirmed in vitro data, that is, most of the new cells identified as astrocytes, some as neurons or oligodendrocytes. These data show the feasibility of the vector approach to induce proliferation and differentiation of neurons and/or oligodendrocytes in vivo.


Asunto(s)
Encéfalo/citología , Vectores Genéticos/metabolismo , Factores de Crecimiento Nervioso/metabolismo , Neuronas/citología , Simplexvirus/genética , Animales , Western Blotting , Encéfalo/metabolismo , Diferenciación Celular , Proliferación Celular , Factor Neurotrófico Ciliar/genética , Factor Neurotrófico Ciliar/metabolismo , Factor 2 de Crecimiento de Fibroblastos/genética , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Masculino , Factores de Crecimiento Nervioso/genética , Ratas , Ratas Sprague-Dawley , Células Madre/citología , Transgenes
6.
Blood ; 97(8): 2514-21, 2001 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-11290617

RESUMEN

In human leukocyte antigen haplotype-mismatched transplantation, extensive T-cell depletion prevents graft-versus-host disease (GVHD) but delays immune recovery. Granulocyte colony-stimulating factor (G-CSF) is given to donors to mobilize stem cells and to recipients to ensure engraftment. Studies have shown that G-CSF promotes T-helper (Th)-2 immune deviation which, unlike Th1 responses, does not protect against intracellular pathogens and fungi. The effect of administration of G-CSF to recipients of mismatched hematopoietic transplants with respect to transplantation outcome and functional immune recovery was investigated. In 43 patients with acute leukemia who received G-CSF after transplantation, the engraftment rate was 95%. However, the patients had a long-lasting type 2 immune reactivity, ie, Th2-inducing dendritic cells not producing interleukin 12 (IL-12) and high frequencies of IL-4- and IL-10-producing CD4(+) cells not expressing the IL-12 receptor beta(2) chain. Similar immune reactivity patterns were observed on exposure of donor cells to G-CSF. Elimination of postgrafting administration of G-CSF in a subsequent series of 36 patients with acute leukemia, while not adversely affecting engraftment rate (93%), resulted in the anticipated appearance of IL-12-producing dendritic cells (1-3 months after transplantation versus > 12 months in transplant recipients given G-CSF), of CD4(+) cells of a mixed Th0/Th1 phenotype, and of antifungal T-cell reactivity in vitro. Moreover, CD4(+) cell counts increased in significantly less time. Finally, elimination of G-CSF-mediated immune suppression did not significantly increase the incidence of GVHD (< 15%). Thus, this study found that administration of G-CSF to recipients of T-cell-depleted hematopoietic transplants was associated with abnormal antigen-presenting cell functions and T-cell reactivity. Elimination of postgrafting administration of G-CSF prevented immune dysregulation and accelerated functional immune recovery.


Asunto(s)
Factor Estimulante de Colonias de Granulocitos/efectos adversos , Movilización de Célula Madre Hematopoyética , Trasplante de Células Madre Hematopoyéticas , Síndromes de Inmunodeficiencia/inducido químicamente , Enfermedad Aguda , Adolescente , Adulto , Aspergillus/inmunología , Recuento de Linfocito CD4 , Candida/inmunología , Niño , Preescolar , Células Dendríticas/inmunología , Susceptibilidad a Enfermedades , Femenino , Supervivencia de Injerto , Enfermedad Injerto contra Huésped/epidemiología , Haplotipos , Humanos , Memoria Inmunológica , Interleucina-10/biosíntesis , Interleucina-12/biosíntesis , Interleucina-4/biosíntesis , Leucemia/inmunología , Leucemia/terapia , Masculino , Persona de Mediana Edad , Subunidades de Proteína , Receptores de Interleucina/biosíntesis , Receptores de Interleucina-12 , Terapia Recuperativa , Células Th2/inmunología , Resultado del Tratamiento
7.
Int Immunol ; 11(7): 1085-92, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10383941

RESUMEN

CD44 is a family of mucin-like membrane proteins generated by alternative splicing of several exons, and participate in T cell adhesion and activation. CD44-mediated signaling involves activation of p56(lck) and leads to ZAP-70 phosphorylation. The aim of the present study was to identify the signaling pathways that follow CD44-triggered ZAP-70 phosphorylation and the molecular mechanisms underlying the CD44 interaction with p56(lck). We found that CD44 cross-linking by mAb in CD4(+) peripheral blood T cells promotes formation of a trimeric complex of Grb2, phospholipase (PLC)-gamma1 and a 36-38 kDa phosphoprotein, and the activation of PLC-gamma1. The amount of inositol triphosphate and the time kinetics of its generation were comparable to those following CD3 cross-linking. Co-capping, co-immunoprecipitation and fluorescence resonance energy transfer experiments showed that CD44 associates with CD4 and CD3 on the cell surface. This association suggests functional interplay between the CD4-TCR complex and CD44. In line with this possibility, we found that CD4 triggering by gp120, a natural ligand of CD4, potentiates CD44-mediated adhesion to hyaluronic acid. Moreover, Ca2+ mobilization induced by CD44 cross-linking by mAb was higher in a subclone of the HUT78 cell line expressing CD4 than in a non-expressing subclone.


Asunto(s)
Antígenos CD4/fisiología , Linfocitos T CD4-Positivos/inmunología , Receptores de Hialuranos/fisiología , Proteína Tirosina Quinasa p56(lck) Específica de Linfocito/fisiología , Transducción de Señal/fisiología , Antígenos CD4/metabolismo , Linfocitos T CD4-Positivos/enzimología , Linfocitos T CD4-Positivos/metabolismo , Activación Enzimática , Humanos , Receptores de Hialuranos/metabolismo , Isoenzimas/metabolismo , Activación de Linfocitos/inmunología , Fosfolipasa C gamma , Fosforilación , Fitohemaglutininas/farmacología , Pruebas de Precipitina , Proteínas Tirosina Quinasas/metabolismo , Proteínas Tirosina Quinasas/fisiología , Fosfolipasas de Tipo C/metabolismo , Proteína Tirosina Quinasa ZAP-70
8.
Blood ; 94(1): 333-9, 1999 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-10381530

RESUMEN

Because of the expression of inhibitory receptors (KIR) for major histocompatibility complex (MHC) class I allotypes, a person's natural killer (NK) cells will not recognize and will, therefore, kill cells from individuals lacking his/her KIR epitopes. This study investigated the role of NK cell alloreactivity in human HLA haplotype-mismatched hematopoietic stem cell transplantation and, specifically, the role of the three major NK specificities, ie, those for HLA-C group 1, HLA-C group 2, and HLA-Bw4 alleles. In 20 of 60 donor-recipient pairs, KIR epitope incompatibility and functional analyses of donor NK cell clones predicted donor NK cells could cause graft-versus-host (GVH)/graft-versus-leukemia (GVL) reactions. NK cell clones of donor origin were obtained from transplanted recipients and tested for lysis of recipient's cryopreserved pretransplant lymphocytes. Despite the absence of GVH disease, we detected high frequencies of NK clones which killed recipient's target cells. Lysis followed the rules of NK cell alloreactivity, being blocked only by the MHC class I KIR epitope which was missing in the recipient. The alloreactive NK clones also killed the allogeneic leukemia. Transplants from these KIR epitope incompatible donors had higher engraftment rates. Therefore, a GVL effector and engraftment facilitating mechanism, which is independent of T-cell-mediated GVH reactions, may be operational in HLA mismatched hematopoietic cell transplants.


Asunto(s)
Citotoxicidad Inmunológica , Efecto Injerto vs Tumor/inmunología , Trasplante de Células Madre Hematopoyéticas , Células Asesinas Naturales/inmunología , Leucemia/terapia , Adolescente , Adulto , Niño , Preescolar , Antígenos HLA , Prueba de Histocompatibilidad , Humanos , Isoantígenos/inmunología , Persona de Mediana Edad , Inmunología del Trasplante , Trasplante Homólogo
9.
J Exp Med ; 189(12): 1855-62, 1999 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-10377181

RESUMEN

This study investigated the role of natural killer (NK) cells as effectors of an immune response against autologous cells modified by gene therapy. T lymphocytes were transduced with LXSN, a retroviral vector adopted for human gene therapy that carries the selectable marker gene neo, and the autologous NK response was evaluated. We found that (i) infection with LXSN makes cells susceptible to autologous NK cell-mediated lysis; (ii) expression of the neo gene is responsible for conferring susceptibility to lysis; (iii) lysis of neo-expressing cells is clonally distributed and mediated only by NK clones that exhibit human histocompatibility leukocyte antigen (HLA)-Bw4 specificity and bear KIR3DL1, a Bw4-specific NK inhibitory receptor; and (iv) the targets are cells from HLA-Bw4(+) individuals. Finally, neo peptides anchoring to the Bw4 allele HLA-B27 interfered with KIR3DL1-mediated recognition of HLA-B27, i.e., they triggered NK lysis. Moreover, neo gene mutations preventing translation of two of the four potentially nonprotective peptides reduced KIR3DL1(+) NK clone-mediated autologous lysis. Thus, individuals expressing Bw4 alleles possess an NK repertoire with the potential to eliminate autologous cells modified by gene therapy. By demonstrating that NK cells can selectively detect the expression of heterologous genes, these observations provide a general model of the NK cell-mediated control of viral infections.


Asunto(s)
Terapia Genética , Células Asesinas Naturales/inmunología , Secuencia de Aminoácidos , Células Clonales , Farmacorresistencia Microbiana/genética , Farmacorresistencia Microbiana/inmunología , Marcadores Genéticos/genética , Antígenos HLA-B/genética , Antígenos HLA-B/inmunología , Antígeno HLA-B27/genética , Antígeno HLA-B27/inmunología , Humanos , Kanamicina Quinasa/genética , Datos de Secuencia Molecular , Mutación , Fragmentos de Péptidos/inmunología , Receptores Inmunológicos/genética , Receptores Inmunológicos/inmunología , Receptores KIR , Receptores KIR3DL1 , Retroviridae/genética , Linfocitos T/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA